THE HISTOPATHOLOGIC AND CLINICAL INDICATORS OF PROGNOSIS IN HEPATOMA
THE HISTOPATHOLOGIC AND CLINICAL INDICATORS OF PROGNOSIS IN HEPATOMA
复制标题
DOI：
10.1097/00004836-198212000-00013
复制
发表时间：
1982-01-01
影响因子：
2.9
通讯作者：
BARWICK, KW
中科院分区：
文献类型：
--
作者：
CHUONG, JJH;LIVSTONE, EM;BARWICK, KW
肝细胞瘤的两种组织病理学亚型，透明细胞型和纤维板层型，已被报道表明生存期较长。虽然透明细胞组织学的预后价值的数据是模棱两可的，延长生存期（平均生存期：32-68个月）的纤维板层型患者的证据是令人印象深刻的。纤维板层型肝细胞癌应行积极的外科治疗，包括转移灶的切除。胆红素测定可能是一个可靠的生存指标，但大多数公认的临床预后标志物的结果相互矛盾的报告。差异性可能反映了肝癌发病机制的地区和种族差异。我们提出了一个说明性的情况下，纤维板层肝癌发现在一个24岁的妇女与游走性血栓性静脉炎。患者成功接受了扩大右肝叶切除术，目前无疾病。我们回顾纤维板层癌和肝癌的组织病理学和临床预后特点。
Two histopathologic subtypes of hepatoma, clear cell type and fibrolamellar type, have been reported to indicate a longer survival. Although data on the prognostic value of clear cell histology is equivocal, evidence for prolonged survival (mean survival: 32–68 months) for patients with fibrolamellar type is impressive. Aggressive surgical intervention, including resection of metastases, appears indicated in fibrolamellar hepatocellular carcinoma. Bilirubin determination may be a reliable indicator of survival, but conflicting results are reported for most reputed clinical prognostic markers. Discrepancies may reflect regional and ethnic differences in the pathogenesis of hepatoma. We present an illustrative case of fibrolamellar hepatoma discovered in a 24-year-old woman with migratory thrombophlebitis. The patient successfully underwent an extended right hepatic lobectomy and is currently free of disease. We review the histopathologic and clinical prognostic features of fibrolamellar carcinoma and hepatoma.